Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines

被引:45
|
作者
Hudson, MA
McReynolds, LM
机构
[1] Division of Urologic Surgery, Washington University, School of Medicine, St. Louis, MO
[2] Division of Urologic Surgery, Washington University, School of Medicine, St. Louis, MO 63110
关键词
D O I
10.1093/jnci/89.10.709
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Purpose: The plasminogen activators urokinase and tissue plasminogen activator are enzymes that degrade proteins in tissue basement membranes and the extracellular matrix (a biomolecular complex surrounding individual cells in tissues that serves as a barrier between the cells and the vascular and lymph systems), The action of these enzymes allows tumor cells to escape their local environment and metastasize. Plasminogen activator activity can be influenced by the urokinase receptor, which is expressed on the surface of cells, and by the plasminogen activator inhibitors 1 and 2. Because bladder tumors differ in their propensity to invade local areas and distant sites, we studied the expression of both plasminogen activators, the two plasminogen activator inhibitors, and the urokinase receptor in four human bladder cancer cell lines (RT4, 253J, EJ, and T24) to see if there was an association between the expression of these proteins and tumor cell invasiveness in vitro, Methods: The expression of urokinase, tissue plasminogen activator, and the two inhibitors was measured by enzyme-linked immunosorbent assays of serum-free, cell-conditioned media (i.e., culture fluids), Cell surface expression of the urokinase receptor was assayed by flow cytometry, using an anti-receptor monoclonal antibody (Mab3936), The invasive capacity of untreated cells and of cells exposed to exogenous, high-molecular-weight urokinase was analyzed by use of Matrigel invasion chambers, Results: The four bladder cancer cell lines demonstrated differential expression of both plasminogen activators and both inhibitors; three of the cell lines (T24, EJ, and 253J) expressed the urokinase receptor, The four cell lines differed in their invasive potential in vitro, Neither expression of tissue plasminogen activator nor production of the inhibitors appeared to influence Matrigel invasion, EJ cells and 253J cells produced the highest levels of urokinase and demonstrated the greatest propensity for invasion; T24 cells, which produced only small amounts of urokinase, exhibited a low invasive potential, Pretreatment of T24 cells with exogenous high-molecular-weight urokinase markedly increased their invasiveness, Similar pretreatment of EJ and 253J cells increased their invasiveness as well, RT4 cells, which lacked urokinase receptor expression but produced moderate amounts of urokinase, were not invasive and did not become so after exposure to exogenous high-molecular-weight urokinase, Binding of Mab3936 to urokinase receptors inhibited Matrigel invasion, Conclusions: To our knowledge, this is the first study demonstrating that bladder tumor cells express the urokinase receptor and that both receptor expression and urokinase expression are required for bladder tumor cell invasion in vitro.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 50 条
  • [21] Urokinase-type plasminogen activator and its receptor in bladder cancer
    Hasui, Y
    Osada, Y
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (10) : 678 - 679
  • [22] Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines
    Li, YH
    Wood, N
    Yellowlees, D
    Donnelly, PK
    ANTICANCER RESEARCH, 1999, 19 (2A) : 1223 - 1228
  • [23] Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes
    Qing Huai
    Aiwu Zhou
    Lin Lin
    Andrew P Mazar
    Graham C Parry
    Jennifer Callahan
    David E Shaw
    Bruce Furie
    Barbara C Furie
    Mingdong Huang
    Nature Structural & Molecular Biology, 2008, 15 : 422 - 423
  • [24] Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes
    Huai, Qing
    Zhou, Aiwu
    Lin, Lin
    Mazar, Andrew P.
    Parry, Graham C.
    Callahan, Jennifer
    Shaw, David E.
    Furie, Bruce
    Furie, Barbara C.
    Huang, Mingdong
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (04) : 422 - 423
  • [25] DETERMINATION OF THE LEVELS OF UROKINASE AND ITS RECEPTOR IN HUMAN-COLON CARCINOMA CELL-LINES
    BOYD, D
    FLORENT, G
    KIM, P
    BRATTAIN, M
    CANCER RESEARCH, 1988, 48 (11) : 3112 - 3116
  • [26] EXPRESSION OF UROKINASE AND ITS RECEPTOR IN INVASIVE AND NONINVASIVE PROSTATE-CANCER CELL-LINES
    HOLLAS, W
    HOOSEIN, N
    CHUNG, LWK
    MAZAR, A
    HENKIN, J
    KARIKO, K
    BARNATHAN, ES
    BOYD, D
    THROMBOSIS AND HAEMOSTASIS, 1992, 68 (06) : 662 - 666
  • [27] Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer
    Carriero, MV
    Del Vecchio, S
    Capozzoli, M
    Franco, P
    Fontana, L
    Zannetti, A
    Botti, G
    D'Aiuto, G
    Salvatore, M
    Stoppelli, MP
    CANCER RESEARCH, 1999, 59 (20) : 5307 - 5314
  • [28] Inhibition of invasiveness of human lung cancer cells by adenovirus-mediated gene transfer of antisense RNA for urokinase receptor
    Sun, XH
    Tan, L
    Li, P
    Zhang, YQ
    Wang, X
    Hou, M
    Song, HY
    Zhu, YS
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2003, 30 (05) : 761 - 766
  • [29] A fully human antibody inhibits urokinase receptor function in vitro.
    Elvin, Paul
    Foltz, Ian
    Kang, Jaspal
    Carragher, Neil
    Emery, Stephen
    Zhou, Qing
    CANCER RESEARCH, 2009, 69
  • [30] Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro
    Abaza, MSI
    Narayan, RK
    Atassi, MZ
    TUMOR BIOLOGY, 1998, 19 (04) : 229 - 237